ChrisA.RhoadesMD

PubMed

• 12 citations
  Multimodal intensification regimens for advanced, resectable, previously untreated squamous cell cancer of the oral cavity, oropharynx, or hypopharynx: a 12-year exper...
  David E. Schuller, Enver Ozer, Amit Agrawal, John C. Grecula, Chris A. Rhoades, Donn C. Young> ;Archives of Otolaryngology--Head & Neck Surgery. 2007 Apr 1
• Phase II study of sequentially administered mitomycin (MMC) and irinotecan (CPT-11) in patients (pts) with metastatic breast cancer (MBC).
  Mrozek E, Kolesar J, Allen J, Young D, Angus D, Kendra K, Rhoades CA, Villalona-Calero MA, Shapiro CL> ;J. Clin. Oncol.. 2006-06-20
• 12 citations
  Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
  Ewa Mrozek, Bhuvaneswari Ramaswamy, Donn C. Young, Chris A. Rhoades, Kari Kendra, Joan Allen, Tim Moore, Marsha Hauger, Holly Watson, Nancy J. Merriman, Padma Nadella,...> ;Clinical Breast Cancer. 2006 Jun 1
• 95 citations
  Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients
  Bhuvaneswari Ramaswamy, Anthony D. Elias, Nicole T. Kelbick, Angela Dodley, Mark Morrow, Marsha Hauger, Joan Allen, Chris A. Rhoades, Kari Kendra, Helen X. Chen, S. Ga...> ;Clinical Cancer Research. 2006 May 15
• 129 citations
  Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients
  J. Paul Monk, Gary Phillips, Ross E. Waite, John G. Kuhn, Larry J. Schaaf, Gregory A. Otterson, Denis C. Guttridge, Chris A. Rhoades, Manisha H. Shah, Tamara Criswell,...> ;Journal of Clinical Oncology. 2006 Apr 20
• 58 citations
  Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)
  Stuart M. Lichtman, Donna Hollis, Antonius A. Miller, Gary L. Rosner, Chris A. Rhoades, Eric P. Lester, Frederick Millard, John C. Byrd, Stephen A. Cullinan, D. Marc R...> ;Journal of Clinical Oncology. 2006 Apr 20
• 15 citations
  Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypophar...
  Enver Ozer, John C. Grecula, Amit Agrawal, Chris A. Rhoades, Donn C. Young, David E. Schuller> ;The Laryngoscope. 2006 Apr 1
• 6 citations
  Intensification regimen for advanced-stage resectable hypopharyngeal carcinoma.
  Enver Ozer, John C. Grecula, Amit Agrawal, Chris A. Rhoades, David E. Schuller> ;Archives of Otolaryngology--Head & Neck Surgery. 2006 Apr 1
• 8 citations
  Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
  Bhuvaneswari Ramaswamy, Steven P. Povoski, Chris A. Rhoades, Joan Allen, Marsha Hauger, Donn C. Young, William E. Burak, William B. Farrar, Lisa D. Yee, Kari Kendra, S...> ;Breast Cancer Research and Treatment. 2005 Sep 1
• 17 citations
  Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients
  Ewa Mrozek, Chris A. Rhoades, Joan Allen, Erinn M. Hade, Charles L. Shapiro> ;Annals of Oncology. 2005 Jul 1
• 2 citations
  Occult primary cancer clinical practice guidelines.
  David S. Ettinger, Juan Pablo Arnoletti, Jon P. Gockerman, Charles R. Handorf, K. A. Havlin, Charlotte Jacobs, Milind Javle, Larry K. Kvols, Renato Lenzi, Asif Rashid,...> ;Journal of the National Comprehensive Cancer Network. 2005 Mar 1
• Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN).
  Rhoades CA, Kraut E, Schuller D, Zhang Y, Chan K, Lang K, Eng C, Grever M> ;J. Clin. Oncol.. 2004-07-15
• 37 citations
  DISEASE CONTROL, SURVIVAL, AND FUNCTIONAL OUTCOME AFTER MULTIMODAL TREATMENT FOR ADVANCED-STAGE TONGUE BASE CANCER
  James P. Malone, Julie A. Stephens, John C. Grecula, Chris A. Rhoades, Bobak A. Ghaheri, David E. Schuller> ;Head & Neck. 2004 Jul 1
• 20 citations
  Multimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx.
  David E. Schuller, John C. Grecula, Amit Agrawal, Chris A. Rhoades, Debra A. Orr, Donn C. Young, James P. Malone, Meredith Merz> ;Cancer. 2002 Jun 15
• 8 citations
  Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas.
  John C. Grecula, David E. Schuller, Roy E. Smith, Chris A. Rhoades, Subir Nag, Constance J. Bauer, Amit Agrawal, Jessie L.-S. Au, Donn C. Young, Reinhard A. Gahbauer> ;Cancer Investigation. 2001 Jul 2
• 10 citations
  Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck.
  John C. Grecula, Roy E. Smith, Chris A. Rhoades, Pramod Sharma, Amit Agrawal, Hong Zhang, James Allen, Federico P. Goldman, Donn C. Young, David E. Schuller> ;Cancer. 2000 Dec 15
• 18 citations
  Intensification regimen 2 for advanced head and neck squamous cell carcinomas.
  John C. Grecula, David E. Schuller, Chris A. Rhoades, Jessie L.-S. Au, Subir Nag, Constance J. Bauer, Amit Agrawal, Rafael Martinez-Monge, Andrew P. Johnson, Donn C. Y...> ;Archives of Otolaryngology--Head & Neck Surgery. 1999 Dec 1
• Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
  Kraut, E. H., Rhoades, C., Zhang, Y., Cheng, H., Aimiumu, J., Chen, P., Lang, J., Young, D. C., Agrawal, A., Dancey, J., Chan, K. K., Grever, M. R.> ;Cancer Chemother Pharmacol. 2011 Mar
• Join now to see all